.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Julphar
AstraZeneca
Teva
Queensland Health
Express Scripts
Colorcon
Merck
McKinsey
Novartis

Generated: December 18, 2017

DrugPatentWatch Database Preview

NASACORT Drug Profile

« Back to Dashboard

When do Nasacort patents expire, and when can generic versions of Nasacort launch?

Nasacort is a drug marketed by Sanofi Aventis Us and is included in three NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in NASACORT is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Eighty-five suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
Drug patent expirations by year for NASACORT

Medical Subject Heading (MeSH) Categories for NASACORT

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis UsNASACORTtriamcinolone acetonideAEROSOL, METERED;NASAL019798-001Jul 11, 1991DISCNNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsNASACORT ALLERGY 24 HOURtriamcinolone acetonideSPRAY, METERED;NASAL020468-002Oct 11, 2013OTCYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsNASACORT ALLERGY 24 HOURtriamcinolone acetonideSPRAY, METERED;NASAL020468-002Oct 11, 2013OTCYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsNASACORT ALLERGY 24 HOURtriamcinolone acetonideSPRAY, METERED;NASAL020468-002Oct 11, 2013OTCYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsNASACORT HFAtriamcinolone acetonideSPRAY, METERED;NASAL020784-001Apr 7, 2004DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for NASACORT

Drugname Dosage Strength RLD Submissiondate
triamcinolone acetonideNasal Spray0.055 mg/SprayNasacort AQ12/29/2005

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Medtronic
Citi
Chinese Patent Office
Accenture
Baxter
Teva
Colorcon
Cipla
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot